Stoush over cost of hormone patches puts Australian women's

Sandoz Australia, the supplier of the drug, recently asked the PBS to increase the price of the patches because the listed cost was no longer sustainable due to manufacturing costs increasing during the Covid-19 pandemic. When the request was refused, Sandoz announced it had requested the products be delisted from the PBS from June, a move that would make the patches available via private prescription only meaning patients would have to pay full price.
It prompted the Australasian Menopause Society, the Royal Australian and New Zealand College of Obstetricians and Gynaecologists, and the Endocrine Society of Australia to write a joint letter to the health minister Greg Hunt to urgently reconsider and to work with Sandoz to strike an agreement.

Related Keywords

Australia , Australian , Estalis Sequi , Greg Hunt , Estradot Estalis , Australasian Menopause Society , Endocrine Society Of Australia , Zealand College Of Obstetricians , Therapeutic Goods Administration , Sandoz Australia , Estalis Continuous , Pharmaceutical Benefits Scheme , Royal Australian , New Zealand College , Endocrine Society , Guy Strong , Australian Register , Therapeutic Goods , ஆஸ்திரேலியா , ஆஸ்திரேலிய , கிரெக் வேட்டை , ஆஸ்ட்ராலேஷியந் மாதவிடாய் சமூகம் , நாளமில்லா சமூகம் ஆஃப் ஆஸ்திரேலியா , ஜீலாந்து கல்லூரி ஆஃப் மகப்பேறியல் , மருந்து நன்மைகள் திட்டம் , அரச ஆஸ்திரேலிய , புதியது ஜீலாந்து கல்லூரி , நாளமில்லா சமூகம் , பையன் வலுவான , ஆஸ்திரேலிய பதிவு , சிகிச்சை பொருட்கள் ,